Oncology, 2020, Suppl.G / Onkologické kazuistiky 6
Case reports
Metastatic cervical carcinoma in situ?
Monika Náležinská, Roman Šefr, Eva Krejčí, Josef Chovanec, Vuk Fait
Onkologie 2020: 14(Suppl.G): 168-170 | DOI: 10.36290/xon.2020.098 
This report presents a case of a 68-year-old patient with a history of cervical carcinoma in situ which was initially treated surgically (laparoscopic vaginal hysterectomy and bilateral salpingo-oophorectomy). Eighteen months after the surgery, the patient was referred back to the gynaeoncological clinic with suspicious liver lesions. Based on the transferred documentation, a metastatic aetiology due to the history of cervical carcinoma in situ was hypothesized. There was a surprising finding of cystic echinococcosis of the liver, which is a rare cause of hepatic tumour in our geographical region. We describe the diagnostic process with a key role...
Long-term control of generalized lung cancer with pembrolizumab
Libor Havel
Onkologie 2020: 14(Suppl.G): 171-174 | DOI: 10.36290/xon.2020.099
So far, platinum doublet chemotherapy has been the only treatment option for patients with advanced non-small cell lung cancer. The only exception were patients with EGFR or ALK mutations in whom treatment with the respective tyrosine kinase inhibitors was the method of choice. With the advent of immunotherapy and a number of positive trials performed in higher lines of treatment, interest has shifted to the first line of treatment. The philosophy of this approach has been to offer patients a more effective as well as less toxic treatment, with a clearly prolonged survival. Two trials with pembrolizumab have been conducted comparing pembrolizumab monotherapy...
Complex karyotype in a younger patient with chronic lymphocytic leukemia
Martin Šimkovič, Lukáš Smolej, Petra Kašparová, Jana Rabasová, Pavlína Havlíková, Dominika Écsiová, Pavel Vodárek, Miriam Lánská, Jakub Radocha, David Belada, Pavel Žák
Onkologie 2020: 14(Suppl.G): 175-178 | DOI: 10.36290/xon.2020.100
Novel therapies directed against B-cell receptor signalling pathways and antiapoptic protein Bcl-2 have improved survival of patients with chronic lymphocytic leukemia (CLL). The unprecedented expansion of therapeutic possibilities has diminished the role of allogeneic hematopoietic cell transplantation (allo-HCT) in CLL. Nevertheless, allo-HCT remains the only potentially curative modality for patients with high-risk disease. The case report describes treatment of a high-risk CLL patient with complex karyotype. In 2019, a 44-years old woman with early progression after FCR underwent ibrutinib treatment for paranasal involvement by CLL. Allo-HCT was...
Pembrolizumab in treating lung adenocarcinoma with malignant pericardial effusion
Juraj Kultan, Ondřej Fischer
Onkologie 2020: 14(Suppl.G): 179-183 | DOI: 10.36290/xon.2020.101
Immunotherapy is a well-established treatment modality for metastatic-stage lung cancer which represent majority of newly diagnosed cases. The most common metastatic sites are: contralateral lung, lymph nodes, brain, adrenal glands, skeleton, and liver. Cardiac involvement is among the less frequent types of lung cancer spread, but it is associated with a worse prognosis in patients. The condition most commonly seen in the clinical practice is pericardial involvement, characterized by accumulation of fluid in the pericardial cavity - malignant pericardial effusion. In some cases it is severe even life-threatening condition associated with impending...
Gastrinoma and its possible complications
Anna Jesenková, Lukáš Sákra, Josef Kubát, Jan Stejskal, Mária Hácová, Irena Vyhnánková
Onkologie 2020: 14(Suppl.G): 184-188 | DOI: 10.36290/xon.2020.102
Gastrinoma belongs to the group of neuroendocrine tumors (NET), which are characterised by secretion of hormonally active substances. The clinical finding is determined especially by the biological effect of the substance and is relatively characteristic. Nevertheless, the diagnostics is often very difficult and it takes months to years to specify the correct diagnosis. The article describes a case report of a patient with this tumor with an emphasis on important moments during diagnostic determination and possible pitfalls arising from conventional therapeutic procedures.
Long-term therapeutic response and complete regression in the treatment of a patient with NSCLC treated with pembrolizumab as first-line monotherapy
Jaromír Roubec, Jaroslav Krátký
Onkologie 2020: 14(Suppl.G): 189-191 | DOI: 10.36290/xon.2020.103
The authors present a case report of a successful treatment by pembrolizumab in an elderly man with adenocarcioma of lung. The aim is to show the case of the successfull anticancer therapy in elderly patient, the today standard therapy by immunotherapy outside of clinical trials in the Czech republic.
Cutaneous angiosarcoma versus anticoagulant - induced hematoma
Zuzana Adamová, Tomáš Bár, Marie Vinahorová, Rostislav Čureček
Onkologie 2020: 14(Suppl.G): 192-194 | DOI: 10.36290/xon.2020.104
Introduction: Our case presentation aims to remind readers of a rare tumor - cutaneous angiosarcoma. Case presentation: We present the case of a 92-year-old patient on chronic anticoagulant therapy presented to hematology outpatient department with spontaneous hematoma on his chest, neck and face. According to his description, the hematoma appearance was sudden with slow progression. Even with normal coagulation parameters the hematoma was enlarging, the patient´s overal condition was worsening. CT of abdomen revealed small multiple lesions in the liver. Biopsy of bruised skin showed an angiosarcoma. Conclusion: Even though the angiosarcoma is so noticeable,...